drug

Riluzole

MeSH D019782
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by King's College London
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia
NCT06270108Early Phase 1Unknown
Treatment of Refractory Schizophrenia With Riluzole
NCT00375050—Completed

KOLs & investigators

2
Oliver D HowesKOL score 29
Zoran Zimolo, MD, Ph.D.

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
King's College London
company
trial
The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia
EARLY_PHASE1
trial
Treatment of Refractory Schizophrenia With Riluzole
NA
trial
indication
Schizophrenia
indication
Treatment-responsive Schizophrenia
indication
Treatment-resistant Schizophrenia
indication
Healthy Controls
indication
KOL
Oliver D Howes
KOL score 29
person
Zoran Zimolo, MD, Ph.D.
KOL score —
person